Cassava Sciences Stock Forecast, Price & News

-33.82 (-32.72 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume25.20 million shs
Average Volume4.55 million shs
Market Capitalization$2.78 billion
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SAVA News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

Cassava Sciences logo

About Cassava Sciences

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.71 out of 5 stars

Medical Sector

873rd out of 2,220 stocks

Pharmaceutical Preparations Industry

427th out of 869 stocks

Analyst Opinion: 3.4Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Cassava Sciences (NASDAQ:SAVA) Frequently Asked Questions

Is Cassava Sciences a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Cassava Sciences stock.
View analyst ratings for Cassava Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Cassava Sciences?

Wall Street analysts have given Cassava Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cassava Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cassava Sciences' next earnings date?

Cassava Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, August 11th 2021.
View our earnings forecast for Cassava Sciences

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) announced its quarterly earnings data on Tuesday, April, 20th. The company reported ($0.09) EPS for the quarter, beating the Zacks' consensus estimate of ($0.10) by $0.01.
View Cassava Sciences' earnings history

How has Cassava Sciences' stock price been impacted by Coronavirus (COVID-19)?

Cassava Sciences' stock was trading at $4.24 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SAVA shares have increased by 1,539.9% and is now trading at $69.53.
View which stocks have been most impacted by COVID-19

When did Cassava Sciences' stock split? How did Cassava Sciences' stock split work?

Cassava Sciences shares reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.

What price target have analysts set for SAVA?

5 equities research analysts have issued twelve-month price objectives for Cassava Sciences' shares. Their forecasts range from $14.00 to $124.00. On average, they anticipate Cassava Sciences' share price to reach $87.25 in the next year. This suggests a possible upside of 25.5% from the stock's current price.
View analysts' price targets for Cassava Sciences
or view top-rated stocks among Wall Street analysts.

Who are Cassava Sciences' key executives?

Cassava Sciences' management team includes the following people:
  • Mr. Remi Barbier, Founder, Chairman, Pres & CEO (Age 61, Pay $936.12k)
  • Mr. Eric J. Schoen, Chief Financial Officer (Age 53, Pay $251.93k)
  • Dr. Nadav Friedmann, Chief Medical Officer & Director (Age 78, Pay $345k)
  • Dr. George Thornton, Sr. VP of Technology
  • Mr. Michael Zamloot, Sr. VP of Technical Operations
  • Dr. Michael Marsman, Sr. VP of Regulatory Affairs
  • Dr. Lindsay H. Burns Ph.D., Sr. VP of Neuroscience
  • Dr. James W. Kupiec M.D., Chief Clinical Devel. Officer

Who are some of Cassava Sciences' key competitors?

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Cutler Group LP (0.00%), Alliancebernstein L.P. (0.11%), IVC Wealth Advisors LLC (0.02%), Golden Green Inc. (0.02%), Investors Financial Group LLC (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Cassava Sciences stock include Eric Schoen, Remi Barbier and Sanford Robertson.
View institutional ownership trends for Cassava Sciences

Which major investors are selling Cassava Sciences stock?

SAVA stock was sold by a variety of institutional investors in the last quarter, including Investors Financial Group LLC.
View insider buying and selling activity for Cassava Sciences
or view top insider-selling stocks.

Which major investors are buying Cassava Sciences stock?

SAVA stock was acquired by a variety of institutional investors in the last quarter, including Cutler Group LP, Alliancebernstein L.P., Zurcher Kantonalbank Zurich Cantonalbank , IVC Wealth Advisors LLC, and Golden Green Inc.. Company insiders that have bought Cassava Sciences stock in the last two years include Eric Schoen, Remi Barbier, and Sanford Robertson.
View insider buying and selling activity for Cassava Sciences
or or view top insider-buying stocks.

How do I buy shares of Cassava Sciences?

Shares of SAVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $69.53.

How much money does Cassava Sciences make?

Cassava Sciences has a market capitalization of $2.78 billion. The company earns $-6,330,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does Cassava Sciences have?

Cassava Sciences employs 11 workers across the globe.

What is Cassava Sciences' official website?

The official website for Cassava Sciences is

Where are Cassava Sciences' headquarters?

Cassava Sciences is headquartered at 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The company can be reached via phone at 512-501-2444 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.